Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2

Neoplasia

Volumn 4, Issue 6, 2002, Pages 501-509

  Messerli, S M ^a   Tang, Y ^a   Giovannini, M ^b   Bronson, R ^c   Weissleder, R ^a   Breakefield, X O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FONDATION JEAN DAUSSET CEPH   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Herpes simplex virus; Magnetic resonance imaging; Neurofibromatosis; Transgenic mice; Tumor

Indexed keywords

EOSIN; GADOLINIUM PENTETATE; HEMATOXYLIN; PROTEIN S 100; MERLIN; TUMOR MARKER;

ABDOMINAL WALL MUSCULATURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EXTERNAL EAR; FEMALE; GENE MUTATION; HERPES SIMPLEX VIRUS 1; IMMUNOHISTOCHEMISTRY; INTERCOSTAL MUSCLE; LEG MUSCLE; MALE; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SCHWANN CELL; SPINAL CORD; SPINAL GANGLION; TRANSGENIC MOUSE; TUMOR LOCALIZATION; ANIMAL; DISEASE MODEL; ENZYME IMMUNOASSAY; GENETICS; HERPES SIMPLEX; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; VIROLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HERPES SIMPLEX; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; NEURILEMMOMA; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036857464     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900265     Document Type: Article

References (41)

1. Louis DN, Stemmer-Rachamimov AO, and Wiestler OD (2000). Neurofibromatosis type 2. World Health Organization Classification of Tumours. Pathology and Genetics, Tumours of the Nervous System. In: Kleihues P, and Cavenee WK (Eds). IARC Press: Lyon, France, pp. 219-22.
2. Eldridge R (1981). Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol 29, 57-65.
3. Mautner VF, Lindenau M, Baser M, Hazim W, Tatagiba M, Haase JW, Samii M, Wais R, and Pulst SM (1996). The neuroimaging and clinical spectrum of neurofibromatosis type 2. Neurosurgery 40, 880-86.
4. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, and Patronas N (1994). Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52, 450-61.
5. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman C, and Plougastel B (1993). Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363, 515-21.
6. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, and Gusella JF (1993). A novel moesin-ezrin-radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72, 791-800.
7. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, Montali E, and Papi L (1996). Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum Genet 97, 632-37.
8. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K, Trofatter JA, Short MP, Bove C, and Eldridge R (1994). Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 55, 314-20.
9. Bianchi AB, Hara T, Ramesh V, Gao J, Szanto-Klein AJ, Morin F, Menon AG, Trofatter JA, Gusella JF, Seizinger BR, and Kley N (1994). Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumor types. Nat Genet 6, 185-92.
10. Bijlsma EK, Merel P, Bosch DA, Westerveld A, Delattre O, Thomas G, and Hulsebos TJ (1994). Analysis of mutations on the SCH gene in schwannomas. Genes Chromosomes Cancer 11, 7-14.
11. Jacoby LB, MacCollin M, Barone R, Ramesh V, and Gusella JF (1996). Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer 17, 45-55.
12. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, and Pulst SM (1994). Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 3, 85-91.
13. Twist EC, Ruttledge MH, Rousseau M, Sanson M, Papi L, Merel P, Delattre O, Thomas G, and Rouleau GA (1994). The neurofibromatosis type 2 gene is inactivated in schwannomas. Hum Mol Genet 3, 147-51.
14. MacCollin M, and Gusella JD (1999). Molecular biology. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis 3rd Ed. In: Friedman JM, Gutmann DH, MacCollin M, and Riccardi VM (Eds). John Hopkins Univ. Press: Baltimore, pp. 351-59.
15. Shaw RJ, McClatchey Al, and Jacks T (1998). Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin. Cell Growth Differ 9, 287-96.
16. Xu L, Gonzalez-Agnosti C, Beauchamp R, Pinney D, Sterner C, and Ramesh V (1998). Analysis of molecular domains of epitope-tagged merlin isoforms in Cos-7 cells and primary rat Schwann cells. Exp Cell Res 238, 231-40.
17. Deguen B, Merel P, Goutebroze L, Giovannini M, Reggio H, Arpin M, and Thomas G (1998). Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton membrane. Hum Mol Genet 7, 217-26.
18. Short MP, Richardson EPJ, Haines JL, and Kwiatkowski DJ (1995). Clinical, neuropathological and genetic aspects of the tuberous sclerosis complex. Brain Pathol 5, 173-79.
19. Renowden SA, and Anslow P (1993). The effective use of magnetic resonance imaging in the diagnosis of acoustic neuromas. Clin Radiol 48, 25-28.
20. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, and Harris R (1992). A clinical study of type 2 neurofibromatosis. Q J Med 84, 603-18.
21. Lam YP, and Breakefield XO (2001). Potential of gene therapy for brain tumors. Hum Mol Genet 10, 777-87.
22. Jane JA, and Helm GA (2000). Gene therapy for skull base tumors. Neurosurg Clin N Am 11, 703-16.
23. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, and Swartz HM (2000). Applications of magnetic resonance in model systems: Cancer therapeutics. Neoplasia 2, 152-65.
24. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, and Breakefield XO (1997). Therapeutic efficacy and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 20, 2057-68.
25. Kramm CM, Rainov NG, Sena-Esteves M, Barnett FH, Chase M, Herrlinger U, Pechan PA, Chiocca EA, and Breakefield XO (1996). Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther 7, 1989-94.
26. Boviatsis EJ, Parks S, Sena-Esteves M, Kramme C, Chase M, Efird JT, Wei M, Breakefield XO, and Chiocca EA (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54, 5745-51.
27. Alavi JB, and Eck SL (2001). Gene therapy for high grade gliomas. Expert Opin Biol Ther 1, 239-52.
28. Kruse CA, Lamb C, Hogan S, Smiley WR, Kleinschmidt-Demasters BK, and Burrows FJ (2000). Purified herpes simplex thymidine kinase retroviral particles. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther 7, 118-27.
29. Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, van der Walk M, Woodruff JM, Goutebroze L, Merel P, Berns A, and Thomas G (1999). Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 15, 978-86.
30. Jacobs A, Breakefield XO, and Fraefel C (1999). HSV-1 based vectors for gene therapy of neurological diseases and brain tumors: Part I HSV-1 structure, replication, and pathogenesis. Neoplasia 1, 387-401.
31. Kreis TE (1986). Microinjected antibodies against the cytoplasmic domain of vesicular stomatitis virus glycoprotein block its transport to the cell surface. EMBO J 5, 931-41.
32. McClatchey Al, Saotome I, Mercer K, Crower D, Gusella JF, Bronson RT, and Jacks T (1998). Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12, 1121-33.
33. Goldstein DJ, and Weller SK (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis; isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62, 196-205.
34. Price J, Turner D, and Cepko C (1987). Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 84, 156-60.
35. Abe T, Kawamura N, Homma H, Sasaki K, Izumiyama H, and Matsumoto K (2000). MRI of orbital schwannomas. Neuroradiology 42, 466-68.
36. Hayasaka K, Tanaka Y, Soeda S, Huppert P, and Claussen CD (1999). MR findings in primary retroperitoneal schwannomas. Acta Radiol 40, 78-82.
37. Hayashi M, Kubo O, Sato H, Taira T, Tajika Y, Izawa M, and Takakura K (1996). Correlation between MR image characteristics and histological features of acoustic schwannoma. Noshuyo Byori 13, 139-44.
38. Soderlund V, Goranson H, and Bauer HC (1994). MR imaging of benign peripheral nerve sheath tumors. Acta Radiol 35, 282-86.
39. Sans A, Brarolami S, and Fraysse B (1996). Histopathology of the peripheral vestibular system in small vestibular schwannomas. Am J Otol 17, 324-26.
40. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Plamer CA, Feigenbaum F, Tornatore C, Tufaro F, and Martuza RL (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7, 867-74.
41. Yoon SS, Carroll NM, Chiocca EA, and Tanabe KK (1998). Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 228, 366-74.